Objectives: The aim of this study was to examine the prognostic value of the preoperative serum α-L-fucosidase (AFU) activity in colorectal cancer and to assess whether it could add prognostic information that Dukes’ stages do not give. Methods: A postoperative follow-up of 137 colorectal cancer patients was performed, and survival analyses were carried out to evaluate the impact of AFU activity on disease-free survival. Dukes’ stage classification, preoperative serum carcinoembryonic antigen levels and six other clinicopathological features of the patients were also analysed. Results: In previous studies, we have stressed the diagnostic value of AFU activity in preoperatively obtained serum from colorectal cancer patients. In the present work, we have found that the enzymatic activity of serum AFU was not related to the Dukes’ stage of the primary tumour, but it was associated with the type of metastasis and recurrence of the disease. The mean value of preoperative serum AFU activity was higher in patients with distant metastases than in those with lymph node or peritoneal metastases, or without metastasis (p = 0.034). After a mean postoperative follow-up period of 22 months, three groups of patients with different recurrence rates could be distinguished (p = 0.0014). Similar results were found when only patients in Dukes’ stage B (p = 0.0439) or C (p = 0.0122) were considered. Conclusions: According to our findings, serum AFU activity appears to be a good prognostic factor of tumour recurrence in colorectal carcinoma. Furthermore, patients in Dukes’ stage B or C at high or very high risk of tumour recurrence could be spotted.

1.
Fenoglio-Preiser CM, Noffsinger G, Franzin G, Zamboni G, Scarpa A, Geboes K: Other tumours of the large intestine; in Whitehead R (ed): Gastrointestinal and Oesophageal Pathology. Edinburgh, Churchill Livingstone, 1995, pp 405–425.
2.
Obrand DI, Gordon PH: Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997;40:5–24.
3.
Dukes CE: The classification of cancer of the rectum. J Pathol Bacteriol 1932;35:323–332.
4.
Astler VB, Coller FA: The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954;139:846–851.
5.
Hermanek P, Sobin LH: UICC TNM Classification of malignant tumours: Colon & Rectum, ed 4, rev 2. London, Springer, 1992, pp 52–56.
6.
American Society of Clinical Oncology: Clinical practice guidelines for the use of tumour markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843–2877.
7.
American Society of Clinical Oncology: 1997 update recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1998;16:793–795.
8.
Desch CE, Benson AB 3rd, Smith TJ, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Petrelli NJ, Pfister DG, Somerfield MR: Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol 1999;17:1312–1321.
9.
McLeod HL, Murray GI: Tumour markers of prognosis in colorectal cancer. Br J Cancer 1999;79:191–203.
10.
Páez de la Cadena M, Fernández J, de Carlos A, Martínez-Zorzano VS, Gil-Martín E, Rodríguez-Berrocal FJ: Low levels of α-L-fucosidase activity in colorectal cancer are due to decreased amounts of the enzymatic protein and are related with Dukes’ stage. Int J Oncol 1996;9:747–754.
11.
Fernández-Rodríguez J, Ayude D, Páez de la Cadena M, Martínez-Zorzano VS, de Carlos A, Caride-Castro A, de Castro G, Rodríguez-Berrocal FJ: α-L-Fucosidase enzyme in the prediction of colorectal cancer patients at high risk of tumour recurrence. Cancer Detect Prev 2000;24:143–149.
12.
Ayude D, Fernández-Rodríguez J, Rodríguez-Berrocal FJ, Martínez-Zorzano VS, de Carlos A, Gil E, Páez de la Cadena M: Value of the serum α-L-fucosidase activity in the diagnosis of colorectal cancer. Oncology 2000;59:310–316.
13.
Fernández-Rodríguez J, Páez de la Cadena M, Martínez-Zorzano VS, Rodríguez-Berrocal FJ: Fucose levels in sera and in tumours of colorectal adenocarcinoma patients. Cancer Lett 1997;121:147–153.
14.
Wang JY, Tang R, Chiang JM: Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum 1994;37:272–277.
15.
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. Am Stat Assoc 1958;53:457–481.
16.
Jass JR, Love SB, Northover JM: A new prognostic classification of rectal cancer. Lancet 1987;i:1303–1306.
17.
Beahrs OH: Colorectal cancer staging as a prognostic feature. Cancer 1982;50:2615–2617.
18.
Chapuis PH, Dent OF, Fisher R, Newland RC, Pheils MT, Smyth E, Colquhoun K: A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 1985;72:698–702.
19.
Wiggers T, Arends JW, Volovics A: Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Colon Rectum 1988;51:33–41.
20.
Hannisdal E, Thorsen G: Regression analysis of prognostic factors in colorectal cancer. J Surg Oncol 1988;37:109–112.
21.
Deugnier Y, David V, Brissot P, Mabo P, Delamaire D, Messner M, Bourel M, Legall JY: Serum α-L-fucosidase: A new marker for the diagnosis of primary hepatic carcinoma? Hepatology 1984;4:889–892.
22.
Bukofer S, Stass PM, Kew MC, de Beer M, Groeneveld HT: Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Southern African blacks. Br J Cancer 1989;59:417–420.
23.
Hutchinson WL, Johnson PJ, Du MQ, Williams R: Serum and tissue α-L-fucosidase activity in the pre-clinical and clinical stages of hepatocellular carcinoma. Clin Sci 1991;81:177–182.
24.
Marotta F, Chui DH, Safran P, Zang SC: Serum α-L-fucosidase: A more sensitive marker for hepatocellular carcinoma? Dig Dis Sci 1991;36:993–997.
25.
Giardina MG, Matarazzo M, Varriale A, Morante R, Napoli A, Martino R: Serum alpha-L-fucosidase: A useful marker in the diagnosis of hepatocellular carcinoma. Cancer 1992;70:1044–1048.
26.
Takahashi H, Saibara T, Iwamura S, Tomita A, Maeda T, Onishi S, Yamamoto Y, Enzan H: Serum α-L-fucosidase activity and tumor size in hepatocellular carcinoma. Hepatology 1994;19:1414–1417.
27.
Neville R, Fielding LP, Amendola C: Local tumour recurrence after curative resection for rectal cancer: A ten-hospital review. Dis Colon Rectum 1986;30:12–17.
28.
Devesa JM, Morales V, Enriquez JM, Nuno J, Camunas J, Hernandez MJ, Avila C: Colorectal cancer. The bases for a comprehensive follow-up. Dis Colon Rectum 1988;31:636–652.
29.
Lindmark G, Gerdin B, Pahlman L, Bergström R, Glimelius B: Prognostic predictors in colorectal cancer. Dis Colon Rectum 1994;37:1219–1227.
30.
Carlsson U, Lasson A, Ekelund G: Recurrence rates after curative surgery for rectal carcinoma. Dis Colon Rectum 1987;30:431–434.
31.
Deans GT, Heatley M, Anderson N, Patterson CC, Rowlands BJ, Parks TG, Spence RA: Jass’ classification revisited. J Am Coll Surg 1994;179:11–17.
32.
Cordero OJ, Ayude D, Nogueira M, Rodríguez-Berrocal FJ, Páez de la Cadena M: Preoperative serum CD26 levels: Diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer 2000;83:1139–1146.
33.
Mulcahy HE, Torner M, Patchett SE, Daly L, O’Donoghue DP: Identifying stage B colorectal cancer patients at high risk of tumor recurrence and death. Dis Colon Rectum 1993;40:326–331.
34.
Palmqvist R, Sellberg P, Öberg A, Tavelin B, Rutegard JN, Stenling R: Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes’ stage B colorectal cancers. Br J Cancer 1999;79:577–581.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.